| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Coronavirus Disease 2019 (COVID-19); Dyslipidemias; Graft vs Host Disease; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Leukemia; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| EXO-CD24 | Phase 2 Clinical | Nano24med, Tel-Aviv Sourasky Medical Center | Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult | Details | |
| ONC-841 | ONC-841 | Phase 1 Clinical | AcroImmune Group | Alzheimer Disease; Neoplasms; Solid tumours | Details |


